New stem cell treatment offers hope for ALS patients

NCT ID NCT06169176

TEMPORARILY_NOT_AVAILABLE Disease control Sponsor: Rapa Therapeutics LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial provides expanded access to RAPA-501, a therapy made from a patient's own immune cells, for people with ALS. The goal is to control the disease and slow its progression. Participants must be 18 or older and have a confirmed ALS diagnosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis Rare Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYOTROPHIC LATERAL SCLEROSIS

Contacts and locations

Show contact details

Locations

Barrow Neurological Institute

Phoenix, Arizona, 85013, United States
Emory University

Atlanta, Georgia, 30322, United States
Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Mayo Clinic Hospital Phoenix

Scottsdale, Arizona, 85259, United States
Providence Portland Medical Center

Portland, Oregon, 97213, United States
University of California Irvine Health

Irvine, California, 92868, United States
University of California, San Francisco

San Francisco, California, 94143, United States
University of Iowa Health Care

Iowa City, Iowa, 52242, United States
University of Minnesota

Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.